Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms: hives ...

A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.

At 2 years, more untreated controls died than those treated with IV edaravone. Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV ...

IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer ...

The first-ever platform trial for ALS tested four drugs simultaneously, creating a faster path to finding treatments for a ...

ALS is a progressive neurodegenerative disease that currently has no cure. Commonly known as Lou Gehrig’s disease, ALS ...

Edaravone dexboneol (Eda.B) is clinically used in China for acute ischemic stroke management as a brain protectant. It consists of two ingredients, edaravone and (+)-dexborneol, exerting antioxidant, ...

However, edaravone is a promising therapeutic agent, although its beneficial effects are inconclusive based on previous systematic reviews and meta-analyses. While several trials in the last 8 years ...

Background: Edaravone dexborneol is a novel cytoprotective agent widely used for acute ischemic stroke patients in clinical practice in China. It is unclear whether minor stroke patients benefit from ...

While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...